Drug Discovery
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Mental Health Portfolio
In a significant move that reshapes the landscape of mental health therapeutics, Johnson & Johnson (NYSE: JNJ) announced today its acquisition of Intra-Cellular...
GSK Makes Strategic $1.15 Billion Move to Acquire IDRx, Strengthening Its Cancer Treatment Portfolio
British pharmaceutical giant GSK has announced its agreement to acquire Boston-based biotechnology firm IDRx for up to $1.15 billion, marking a significant expansion...
Murali Divi: The Visionary Behind Divi’s Laboratories
Murali Divi, a U.S.-trained scientist and entrepreneur, is a prominent name in the global pharmaceutical industry. His journey is a testament to vision,...
The Visionary Leadership of Li Ge: A Trailblazer in Biotech and Pharmaceutical Innovation
Li Ge, a pioneering figure in the global biotech and pharmaceutical industries, has made an indelible mark as the chairman and CEO of...
David Shaw: The Visionary Behind D.E. Shaw and Computational Biochemistry
David Shaw is a name that stands out in the worlds of finance, technology, and computational science. As the founder of D.E. Shaw...
Gong Hongjia & Family: A Visionary Investor with Diverse Interests
Gong Hongjia is a prominent Chinese investor whose wealth and influence have been built through strategic investments in various high-growth sectors, from surveillance...
Zhao Ning: A Visionary Leader in Pharmaceutical Research
Zhao Ning, a pioneering figure in pharmaceutical research and cofounder of the globally acclaimed WuXi AppTec, left an enduring legacy in the healthcare...
Feng Yuxia: Steering Joinn Laboratories Toward Global Leadership in Medical Services
In the ever-evolving landscape of global healthcare, few figures have made as indelible a mark as Feng Yuxia, the visionary chair of Joinn...
